Hi everybody and welcome at our podcast in Good Company. I'm Nicola Tangen, the CEO of the

Norwegian someone welfare. In this podcast, I talk to the leaders of some of the largest companies

we are invested in so that you can learn what we own and meet these impressive leaders. Today, I'm

speaking to Lars Fugard Jorgensen, the CEO of Nordo Nordisk, the second largest pharma company in the world.

Lars is a bit like a quiet assassin, really, really impressive.

Nova's goal is to defeat some of the biggest health challenges the world is facing, such as obesity.

We own almost 2% of Nova Nordisk, translating into 57 billion crowner or almost 6 billion

US dollars. This was a truly amazing conversation. Stay tuned.

So, Lars, very welcome to the podcast.

Nova Nordisk has got an unrivaled reputation worldwide, so it's fantastic to have you on.

Thank you, Nibla.

It's in order to be here.

Now, I thought I'd kick off on obesity, because it's such a big problem.

And it's triples in 75, more than 1 billion people are obese.

And I read somewhere that it now accounts for nearly the cost of obesity, nearly accounts for

3% of world GDP.

Now, what are the drivers behind this?

It's interesting to reflect on obesity and the fact that it's now being recognized as a

disease, not among all, but increasingly. And until now, there has not been real efficacious medicine.

And when you don't have efficacious medicine, often the medical community is not highly engaged in a disease.

So what's happening now is that we acknowledge that it's not just about lifestyle,

it's not just about how much we eat, it's actually about genetics,

...